Welcome to our dedicated page for Yubo International Biotech SEC filings (Ticker: YBGJ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Yubo International Biotech's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Yubo International Biotech's regulatory disclosures and financial reporting.
Yubo International Biotech Limited is a New York holding company whose China operations run through a Cayman and Hong Kong structure and contractual arrangements with a Chinese variable interest entity, Yubo Beijing. Investors in Class A shares hold no direct equity in the PRC operating companies.
Yubo Beijing focuses on endometrial stem cell technologies, aiming to build what it describes as the first public endometrial stem cell bank and selling “VIVCELL” branded light application products for respiratory health, skincare, hair care, beverages, and personal care in China. The VIE structure and related contracts have not been tested in court and could be invalidated or restricted by PRC authorities.
The company highlights extensive risks from evolving Chinese regulation on foreign investment, data security, cybersecurity review, overseas offerings, and potential HFCAA-related trading prohibitions. It reports a history of losses and expresses substantial doubt about its ability to continue as a going concern, while revenue in 2025 came from a single customer buying light application products.
Yubo International Biotech Limited reported a change in its independent auditor. On January 13, 2026, HHL LLP resigned as the company’s independent registered public accounting firm, and the board of directors accepted the resignation effective immediately. HHL’s audit report on the year ended December 31, 2024 contained no adverse or disclaimed opinion and was not qualified, other than an explanatory paragraph highlighting substantial doubt about the company’s ability to continue as a going concern.
For the fiscal years ended December 31, 2025 and December 31, 2024, and the interim period through January 13, 2026, the company states there were no disagreements with HHL on accounting principles, financial disclosures, or audit procedures, and no reportable events under SEC rules. The company engaged HCL, PLLC as its new independent registered public accountant on January 13, 2026 to audit the consolidated financial statements for the year ended December 31, 2025, and indicates it did not previously consult HCL on specific accounting issues or potential audit opinions.
Yubo International Biotech Limited reported its quarterly results for the period ended September 30, 2025. The company generated no revenue and recorded a net loss of $310,152 for the quarter and $902,288 for the nine months. Operating expenses were $310,134 in the quarter, reflecting spending on compensation, occupancy, and depreciation.
On the balance sheet, cash was $10,926, total assets were $953,211, and total liabilities were $2,555,316, resulting in a shareholders’ deficit of $1,602,105. Management disclosed substantial doubt about the company’s ability to continue as a going concern, citing a working capital deficit of $1,905,753. During the quarter, the company issued 50,600,343 Class A shares at $0.05 per share to FlyDragon and ChinaOne, settling $2,530,000 of shareholder loans. Shares outstanding as of November 13, 2025 were 170,416,343 Class A and 4,447 Class B.
The company operates in China through a VIE structure (Yubo Beijing). Investors in Class A shares do not hold equity in the PRC operating entities, and the filing highlights risks that PRC authorities could disallow the contractual arrangements.